BEGIN:VCALENDAR
VERSION:2.0
PRODID:www.dresden-science-calendar.de
METHOD:PUBLISH
CALSCALE:GREGORIAN
X-MICROSOFT-CALSCALE:GREGORIAN
X-WR-TIMEZONE:Europe/Berlin
BEGIN:VTIMEZONE
TZID:Europe/Berlin
X-LIC-LOCATION:Europe/Berlin
BEGIN:DAYLIGHT
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
DTSTART:19810329T030000
RRULE:FREQ=YEARLY;INTERVAL=1;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;INTERVAL=1;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:DSC-10683
DTSTART;TZID=Europe/Berlin:20160317T143000
SEQUENCE:1453972895
TRANSP:OPAQUE
DTEND;TZID=Europe/Berlin:20160317T160000
URL:https://dresden-science-calendar.de/calendar/en/detail/10683
LOCATION:Institut für Medizinische Informatik und Biometrie (IMB)\, Blasew
 itzer Straße 8601307 Dresden
SUMMARY:Arndt: Antibody-based retargeting strategies for tumor immunotherap
 y
CLASS:PUBLIC
DESCRIPTION:Speaker: Claudia Arndt \nInstitute of Speaker: Helmholtz-Zentru
 m Dresden-Rossendorf\nTopics:\nBiologie\, Medizin\n Location:\n  Name: Ins
 titut für Medizinische Informatik und Biometrie (IMB) (Haus 105\, Blasewi
 tzer Straße 86\, 3rd floor\, room 3.465)\n  Street: Blasewitzer Straße 8
 6\n  City: 01307 Dresden\n  Phone: \n  Fax: \nDescription: Over the past d
 ecades\, it was shown that a cross-linkage of T cells with tumor cells can
  lead to an activation of the T cells and\, as a consequence\, to a destru
 ction of the tumor cells. Such a cross-linkage can artificially be achieve
 d by single-chain bispecific antibodies (bsAbs). In principle\, they are c
 reated from the variable domains of two different monoclonal Abs: one dire
 cted against a target antigen on the surface of the tumor cell and another
  one directed against an activating receptor of the T cell\, most commonly
  the CD3 complex of the T cell receptor. For redirection of T cells to hem
 atologic malignancies and solid tumors we designed different bsAb. As unde
 rlined by in vitro and in vivo data these bsAbs are promising candidates f
 or cancer immunotherapy.  In order to further reduce the risk of side effe
 cts and accelerate the development of conventional bsAbs\, we additionally
  developed a Lego-like modular targeting platform. For this purpose\, the 
 conventional bsAb was split into two components which are termed effector 
 and target module. It was shown that the modular system can functionally r
 eplace conventional bsAbs both in vitro and in vivo. Due to its dual chara
 cter this novel platform technology not only exhibits a higher flexibility
  but also opens the door for multiple as well as multifunctional tumor tar
 geting. Overall\, our bsAbs as well as the modular Ab-platform represent f
 lexible\, valuable and promising tools for cancer immunotherapy. 
DTSTAMP:20260612T103026Z
CREATED:20160128T092135Z
LAST-MODIFIED:20160128T092135Z
END:VEVENT
END:VCALENDAR